| Literature DB >> 32355874 |
Ricardo Hannum Resende1, Igor Braga Ribeiro1, Diogo Turiani Hourneaux de Moura1,2, Facundo Galetti1, Rodrigo Silva de Paula Rocha1, Wanderley Marques Bernardo1, Paulo Sakai1, Eduardo Guimarães Hourneaux de Moura1.
Abstract
Background and study aims Ulcerative colitis (UC) and Crohn's disease (CD) have higher risk of colorectal cancer (CRC). Guidelines recommend dysplasia surveillance with dye-spraying chromoendoscopy (DCE). The aim of this systematic review and meta-analysis was to review all randomized clinical trials (RCTs) available and compare the efficacy of different endoscopic methods of surveillance for dysplasia in patients with UC and CD. Methods Databases searched were Medline, EMBASE, Cochrane and SCIELO/LILACS. It was estimated the risk difference (RD) for dichotomous outcomes (number of patients diagnosed with one or more dysplastic lesions, total number of dysplastic lesions diagnosed and number of dysplastic lesions detected by targeted biopsies) and mean difference for continuous outcomes (procedure time). Results This study included 17 RCTs totaling 2,457 patients. There was superiority of DCE when compared to standard-definiton white light endoscopy (SD-WLE). When compared with high-definition (HD) WLE, no difference was observed in all outcomes (number of patients with dysplasia (RD 0.06; 95 % CI [-0.01, 0.13])). Comparing other techniques, no difference was observed between DCE and virtual chromoendoscopy (VCE - including narrow-band imaging [NBI], i-SCAN and flexible spectral imaging color enhancement), in all outcomes except procedure time (mean difference, 6.33 min; 95 % CI, 1.29, 11.33). DCE required a significantly longer procedure time compared with WLE (mean difference, 7.81 min; 95 % CI, 2.76, 12.86). Conclusions We found that dye-spraying chromoendoscopy detected more patients and dysplastic lesions than SD-WLE. Although no difference was observed between DCE and HD-WLE or narrow-band imaging, the main outcomes favored numerically dye-spraying chromoendoscopy, except procedure time. Regarding i-SCAN, FICE and auto-fluorescence imaging, there is still not enough evidence to support or not their recommendation.Entities:
Year: 2020 PMID: 32355874 PMCID: PMC7174005 DOI: 10.1055/a-1120-8376
Source DB: PubMed Journal: Endosc Int Open ISSN: 2196-9736
Fig. 1Flow diagram of the study.
Characteristics of the included studies.
| Study |
Gulati
|
Iacucci
|
Bisschops
|
Vleugels
|
Alexandersson
|
Park
|
Watanabe
|
Cassinoti
|
Mohammed
|
Freire
|
Ignjatovic
|
Feitosa
|
Pellisé
|
Van den Broek
|
Van den Broek
|
Kiesslich
|
Kiesslich
|
| Year | 2018 | 2018 | 2018 | 2018 | 2018 | 2016 | 2016 | 2015 | 2015 | 2014 | 2012 | 2011 | 2011 | 2011 | 2008 | 2007 | 2003 |
| Type and design of study | Article, Parallel | Article, Parallel | Article, Parallel | Article, Parallel | Abstract, Parallel | Abstract, Parallel | Abstract, Parallel | Abstract, Parallel | Abstract, Parallel | Article, Parallel | Article, Parallel | Abstract, Parallel | Article, Crossover | Article, Crossover | Article, Crossover | Article, Parallel | Article, Parallel |
| Endoscopic technique comparation | DCE, FICE | DCE, HD-WLE, i-SCAN | DCE, NBI | DCE, AFI | DCE, SD-WLE | DCE, HD-WLE | DCE, NBI | SD-WLE, FICE | DCE, HD-WLE | DCE, SD-WLE | HD-WLE, NBI | DCE, NBI | DCE, NBI | HD-WLE, NBI | AFI, HD-WLE | DCE, SD-WLE | DCE, SDWLE |
| Type of dye | Indigo carmine | Indigo carmine | Methylene Blue | Indigo carmine and Methylene Blue | Indigo carmine | Indigo carmine | Indigo carmine | NA | Indigo carmine | Methylene Blue | NA | NA | Indigo carmine | NA | NA | Methylene Blue | Methylene Blue |
| Patients, n | 60 | 270 | 157 | 210 | 305 | 210 | 263 | 91 | 103 | 162 | 112 | 29 | 60 | 48 | 50 | 153 | 174 |
| Type of IBD (patients, n) | UC (45), CD (03), | UC (129), CD (136), IC (5) | UC (157) | UC (210) | UC (NA), CD (NA) | UC (210) | UC (263) | UC (91) | UC (103) | UC (162) | UC (112) | UC (13), CD (16) | UC (42), CD (19) | UC (48) | UC (50) | UC (161) | UC (174) |
| Mean age (SD), y | 41 (12) to 48 (15) | 48 (14) to 50 (12) | 52 (14) to 52.5 (13) | 56 (12) | 50 | NA | 51 | NA | 54 (14) to 56 (16) | 49 (13) to 52 (16) | 52 (11) to 53 (14) | 49 to 50 | 47 (13) to 49 (15) | 56 (11) | 50 (11) to 51 (13) | 42 (20) to 46 (23) | 39 (9) to 42 (12) |
| Sex M/F | 30/18 | 148/122 | 73/58 | 122/88 | 210/95 | NA | 136/127 | NA | 74/88 | 65/47 | 10/19 | 33/27 | 35/13 | 31/19 | NA | ||
| Duration of IBD (SD), y | 12 (5) to 17 (7) | 16 (10) to 19 (10) | 14 (9) to 16 (9) | 19 (10) to 22 (13) | NA | NA | 13 | NA | 22 (13) to 22 (11) | 16 (10) to 18 (8) | 21 (10) to 21 (11) | 15 (6) to 16 (9) | 15 (7) to 17 (9) | 23 (10) | 14 (6) to 16 (7) | 12 (9) to 14 (8) | 10 (6) to 11 (7) |
| Left-sided (UC) | NA | 49 | 54 | 68 | NA | NA | NA | NA | 0 | 79 | 16 | NA | NA | 0 | 0 | 53 | 54 |
| Pancolitis (UC) | 36 | 79 | 75 | 142 | NA | NA | NA | NA | 103 | 66 | 96 | NA | 43 | 48 | 50 | 38 | 83 |
| History of dysplasia, n | 5 | 60 | NA | 34 | NA | NA | 15 | NA | NA | 0 | 9 | NA | 8 | 9 | 7 | NA | 0 |
| Family history of CCR, n | 2 | 29 | NA | 34 | NA | NA | 7 | NA | 6 | 23 | 14 | NA | 8 | 7 | NA | NA | 8 |
| Personal history of PSC, n | 24 | 35 | 13 | 38 | NA | NA | 2 | NA | 19 | 0 | 4 | NA | 5 | 8 | 7 | 15 | 19 |
Fig. 2DCE versus WLE: number of patients diagnosed with one or more dysplastic lesions.
Fig. 3DCE versus WLE: total number of dysplastic lesions detected.
Fig. 4DCE versus WLE: procedure time.
Fig. 5DCE versus VCE: number of patients diagnosed with one or more dysplastic lesions.
Fig. 6DCE versus VCE: total number of dysplastic lesions detected.
Fig. 7DCE versus VCE: procedure time.